| HealthPartners | Mucopolysaccharidoses (MPS) drug therapy – | 2025-10-01 |
| HealthPartners | Omadacycline (Nuzyra®) – Minnesota Healthcare | 2025-10-01 |
| HealthPartners | Omidubicel-onlv (Omisirge®) | 2025-10-01 |
| HealthPartners | Oncology - gene therapy for bladder cancer | 2025-10-01 |
| HealthPartners | Oncology** - denosumab (Prolia® and Xgeva®) – | 2025-10-01 |
| HealthPartners | Oncology ** - denosumab (Prolia®, Xgeva®) | 2025-10-01 |
| HealthPartners | Pompe disease enzyme replacement therapy: | 2025-10-01 |
| HealthPartners | Pompe disease enzyme replacement therapy: | 2025-10-01 |
| HealthPartners | Satralizumab-mwge (Enspryng™) and inebilizumab- | 2025-10-01 |
| HealthPartners | Satralizumab-mwge (Enspryng™) and inebilizumab- | 2025-10-01 |